文献速递精神分裂症与精神病性障碍老年精神

绝经期激素治疗预防精神分裂症或分裂情感性障碍女性复发的真实世界有效性

Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
PubMed 文献 · Am J Psychiatry · 2024-09-12

芬兰全国队列中40-62岁精神分裂症或分裂情感性障碍女性使用绝经期激素治疗(MHT)与精神病复发风险降低16%相关(aHR=0.84,95%CI=0.78-0.90),40-55岁使用有效,56-62岁未达统计学显著,替勃龙和地屈孕酮制剂未显示关联。

要点

  • MHT使用与精神病复发风险降低16%相关(aHR=0.84,95%CI=0.78-0.90)。
  • 40-49岁(aHR=0.86,95%CI=0.78-0.95)和50-55岁(aHR=0.74,95%CI=0.66-0.83)使用MHT与复发风险降低相关。
  • 56-62岁使用MHT与复发风险无显著关联(aHR=1.11,95%CI=0.91-1.37)。

核心结论

  • 研究结果强调MHT在预防绝经年龄精神分裂症或分裂情感性障碍女性精神病复发方面具有潜在价值。
  • 这些发现将雌激素神经保护作用的临床证据转化至真实世界环境,涵盖当前抗精神病治疗选择可能不足的女性群体。

研究设计与样本

  • 采用个体内研究设计,基于芬兰全国队列,纳入1994-2017年随访期间使用MHT的40-62岁精神分裂症或分裂情感性障碍女性。
  • 研究人群包括3,488名使用MHT的女性。
  • 计算了校正年龄和精神药物使用的风险比,主要结局为精神病复发,次要结局为任何精神科住院。

主要发现

  • 与未使用MHT相比,使用MHT与复发风险降低16%相关(aHR=0.84,95%CI=0.78-0.90)。
  • 按年龄分层,40-49岁使用MHT与复发风险降低相关(aHR=0.86,95%CI=0.78-0.95),50-55岁使用与复发风险降低相关(aHR=0.74,95%CI=0.66-0.83),56-62岁使用与复发风险无显著关联(aHR=1.11,95%CI=0.91-1.37)。
  • 单用雌激素或联合固定或序贯孕激素、经皮和口服制剂以及大多数具体制剂的有效性相似(aHR在0.75-0.87之间),但替勃龙(aHR=1.04,95%CI=0.75-1.44)和含地屈孕酮制剂(aHR=1.05,95%CI=0.85-1.30)除外。
  • 以任何精神科住院为结局指标时观察到相似结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antipsychotic effectiveness in preventing relapse declines around menopausal age in women with schizophrenia or schizoaffective disorder (SSD). It is not known whether systemic menopausal hormone therapy (MHT) can help to prevent psychosis relapse. METHODS: A within-subject study design was used to study the effectiveness of MHT in preventing relapse in a Finnish nationwide cohort of women with SSD between 40 and 62 years of age who used MHT during follow-up (1994-2017). Hazard ratios adjusted for age and psychotropic drug use were calculated for psychosis relapse as main outcome and any psychiatric hospitalization as secondary outcome. RESULTS: The study population comprised 3,488 women using MHT. Use of MHT was associated with a 16% lower relapse risk (adjusted hazard ratio [aHR]=0.84, 95% CI=0.78-0.90) when compared to non-use. Stratified by age, MHT was associated with decreased relapse risks when used between ages 40-49 (aHR=0.86, 95% CI=0.78-0.95) and ages 50-55 (aHR=0.74, 95% CI=0.66-0.83), but not between ages 56-62 (aHR=1.11, 95% CI=0.91-1.37). Similar effectiveness was found for estrogen alone or combined with fixed or sequential progestogens (aHRs between 0.79 and 0.86), transdermal and oral formulations (aHRs 0.75-0.87), and for most specific formulations (aHRs 0.75-0.85), except tibolone (aHR=1.04, 95% CI=0.75-1.44) and formulations with dydrogesterone (aHR=1.05, 95% CI=0.85-1.30). Similar results were observed with any psychiatric hospitalization as outcome measure. CONCLUSIONS: The findings underscore the potential value of MHT in preventing psychosis relapse among women with SSD of menopausal age. These findings translate clinical evidence on the neuroprotective effects of estrogens to real-world settings, encompassing a group of women for whom current antipsychotic treatment options may be insufficient.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brand BA, Sommer IE, Gangadin SS, et al. Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder. Am J Psychiatry. 2024. PMID: 39262210. doi:10.1176/appi.ajp.20230850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。